UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 174

Sortiert nach

Impact of Human Immunodeficiency Virus Type 1 gp41 Amino Acid Substitutions Selected during Enfuvirtide Treatment on gp41 Binding and Antiviral Potency of Enfuvirtide In Vitro

Journal of Virology, 2005-10, Vol.79 (19), p.12447-12454

2005

Link zum Volltext

Verfügbarkeit prüfen

Characterization of envelope glycoprotein gp41 genotype and phenotypic susceptibility to enfuvirtide at baseline and on treatment in the phase III clinical trials TORO-1 and TORO-2

AIDS research and human retroviruses, 2006-05, Vol.22 (5), p.375

2006

Link zum Volltext

Verfügbarkeit prüfen

HIV fusion and its inhibition in antiretroviral therapy

Reviews in medical virology, 2004-09, Vol.14 (5), p.321-337

2004

Link zum Volltext

Verfügbarkeit prüfen

959 SUBTYPE SPECIFIC RESISTANCE PROFILES AFTER SELECTION OF HCV GENOTYPE 1A OR GENOTYPE 1B REPLICONS WITH TELAPREVIR OR HCV-796

Journal of hepatology, 2009, Vol.50, p.S348-S349

2009

Link zum Volltext

Verfügbarkeit prüfen

Evolution of genotypic and phenotypic resistance during chronic treatment with the fusion inhibitor T-1249

AIDS research and human retroviruses, 2007-11, Vol.23 (11), p.1366

2007

Link zum Volltext

Verfügbarkeit prüfen

960 SUPPRESSION OF IN VITRO RESISTANCE DEVELOPMENT AFTER TREATMENT OF THE HCV REPLICON WITH NS3/4A INHIBITOR ITMN-191 (R7227) IN COMBINATION WITH NUCLEOSIDE INHIBITOR R7128 OR R1626

Journal of hepatology, 2009, Vol.50, p.S349-S349

2009

Link zum Volltext

Verfügbarkeit prüfen

High-level resistance to (-) enantiomeric 2'-deoxy-3'-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase

Antimicrobial Agents and Chemotherapy, 1993-10, Vol.37 (10), p.2231-2234

1993

Link zum Volltext

Verfügbarkeit prüfen

A GABA transporter operates asymmetrically and with variable stoichiometry

Neuron (Cambridge, Mass.), 1994-10, Vol.13 (4), p.949-960

1994

Link zum Volltext

Verfügbarkeit prüfen

Channel behavior in a gamma-aminobutyrate transporter

Proceedings of the National Academy of Sciences - PNAS, 1996-01, Vol.93 (2), p.723-727

1996

Link zum Volltext

Verfügbarkeit prüfen

The potential for HIV fusion inhibition

Current opinion in infectious diseases, 2001-02, Vol.14 (1), p.13-16

Cammack, Nick

2001

Link zum Volltext

Verfügbarkeit prüfen

[603] R1479, A NOVEL NUCLEOSIDE ANALOG AND POTENT INHIBITOR OF HCV REPLICATION, DOES NOT AFFECT RIBAVIRIN-INDUCED HEMOLYSIS AND ERYTHROCYTE FRAGILITY IN VITRO

Journal of hepatology, 2007, Vol.46, p.S228-S228

2007

Link zum Volltext

Verfügbarkeit prüfen

The same mutation that encodes low-level human immunodeficiency virus type 1 resistance to 2',3'-dideoxyinosine and 2',3'-dideoxycytidine confers high-level resistance to the (-) enantiomer of 2',3'-dideoxy-3'-thiacytidine

Antimicrobial Agents and Chemotherapy, 1993-06, Vol.37 (6), p.1390-1392

1993

Link zum Volltext

Verfügbarkeit prüfen

Resistance to enfuvirtide, the first HIV fusion inhibitor

Journal of antimicrobial chemotherapy, 2004-08, Vol.54 (2), p.333-340

2004

Link zum Volltext

Verfügbarkeit prüfen

[790] IN VITRO RESISTANCE SELECTION TO THE HCV NUCLEOSIDE POLYMERASE INHIBITOR R1479 AND TO THE PROTEASE INHIBITOR VX-950

Journal of hepatology, 2007, Vol.46, p.S297-S298

2007

Link zum Volltext

Verfügbarkeit prüfen

In vitro resistance development for RO-0335, a novel diphenylether nonnucleoside reverse transcriptase inhibitor

Antiviral research, 2010-05, Vol.86 (2), p.212-219

2010

Link zum Volltext

Verfügbarkeit prüfen

The separated enantiomers of 2'-deoxy-3'-thiacytidine (BCH 189) both inhibit human immunodeficiency virus replication in vitro

Antimicrobial Agents and Chemotherapy, 1992-01, Vol.36 (1), p.202-205

1992

Link zum Volltext

Verfügbarkeit prüfen

951 SILIBININ INHIBITS HCV REPLICATION IN VITRO

Journal of hepatology, 2009, Vol.50, p.S346-S346

2009

Link zum Volltext

Verfügbarkeit prüfen

21 LOW LEVEL OF RESISTANCE, LOW VIRAL FITNESS AND ABSENCE OF RESISTANCE MUTATIONS IN BASELINE QUASISPECIES MAY CONTRIBUTE TO HIGH BARRIER TO R1626 RESISTANCE IN VIVO

Journal of hepatology, 2008, Vol.48, p.S10-S10

2008

Link zum Volltext

Verfügbarkeit prüfen

952 2′ -DEOXY-NUCLEOSIDE ANALOGS AS POTENT DUAL INHIBITORS OF HCV AND HIV REPLICATION, WITH SELECTIVITY AGAINST OTHER VIRAL AND HUMAN POLYMERASES

Journal of hepatology, 2009, Vol.50, p.S346-S346

2009

Link zum Volltext

Verfügbarkeit prüfen

Existence of hepatitis C virus NS5B variants naturally resistant to non-nucleoside, but not to nucleoside, polymerase inhibitors among untreated patients

Journal of antimicrobial chemotherapy, 2008-06, Vol.61 (6), p.1205-1216

2008

Link zum Volltext

Verfügbarkeit prüfen

851 ANTIVIRAL POTENCY OF R1479, ACTIVE COMPOUND DERIVED IN VIVO FROM PRODRUG R1626, DEMONSTRATED ACROSS HCV GENOTYPES 1-6 IN NS5B RECOMBINANT ENZYMES AND HCV REPLICONS

Journal of hepatology, 2008, Vol.48, p.S319-S319

2008

Link zum Volltext

Verfügbarkeit prüfen

[622] R1479, A NOVEL HEPATITIS C POLYMERASE INHIBITOR: LACK OF PRE-EXISTING RESISTANCE MUTATION SUPPORTS THE OBSERVED IN VIVO HIGH BARRIER TO RESISTANCE

Journal of hepatology, 2007, Vol.46, p.S235-S235

2007

Link zum Volltext

Verfügbarkeit prüfen

(-)-2'-deoxy-3'-thiacytidine is a potent, highly selective inhibitor of human immunodeficiency virus type 1 and type 2 replication in vitro

Antimicrobial Agents and Chemotherapy, 1992-04, Vol.36 (4), p.733-739

1992

Link zum Volltext

Verfügbarkeit prüfen

Ions required for the electrogenic transport of GABA by horizontal cells of the catfish retina

The Journal of physiology, 1993-12, Vol.472 (1), p.81-102

1993

Link zum Volltext

Verfügbarkeit prüfen

Evaluation of Reproductive Development Following Intravenous and Oral Exposure to DEHP in Male Neonatal Rats

International journal of toxicology, 2003-05, Vol.22 (3), p.159-174

2003

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 174

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(158)
Mit Volltextzugriff
(157)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(97)
Life Sciences & Biomedicine
(82)
Biological And Medical Sciences
(60)
Humans
(49)
Medical Sciences
(36)
Virology
(35)
Fundamental And Applied Biological Sciences. Psychology
(32)
Microbiology
(30)
Animals
(25)
Aids/hiv
(24)
Infectious Diseases
(24)
Antibiotics. Antiinfectious Agents. Antiparasitic Agents
(23)
Antiviral Agents
(23)
Biochemistry & Molecular Biology
(23)
Pharmacology. Drug Treatments
(23)
Pharmacology & Pharmacy
(19)
Cell Line
(18)
Human Immunodeficiency Virus
(17)
Hiv-1 - Drug Effects
(16)
Human Immunodeficiency Virus 1
(16)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Impact of Human Immunodeficiency Virus Type 1 gp41 Amino Acid Substitutions Selected during Enfuvirtide Treatment on gp41 Binding and Antiviral Potency of Enfuvirtide In Vitro

Characterization of envelope glycoprotein gp41 genotype and phenotypic susceptibility to enfuvirtide at baseline and on treatment in the phase III clinical trials TORO-1 and TORO-2

HIV fusion and its inhibition in antiretroviral therapy

959 SUBTYPE SPECIFIC RESISTANCE PROFILES AFTER SELECTION OF HCV GENOTYPE 1A OR GENOTYPE 1B REPLICONS WITH TELAPREVIR OR HCV-796

Evolution of genotypic and phenotypic resistance during chronic treatment with the fusion inhibitor T-1249

960 SUPPRESSION OF IN VITRO RESISTANCE DEVELOPMENT AFTER TREATMENT OF THE HCV REPLICON WITH NS3/4A INHIBITOR ITMN-191 (R7227) IN COMBINATION WITH NUCLEOSIDE INHIBITOR R7128 OR R1626

High-level resistance to (-) enantiomeric 2'-deoxy-3'-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase

A GABA transporter operates asymmetrically and with variable stoichiometry

Channel behavior in a gamma-aminobutyrate transporter

The potential for HIV fusion inhibition

[603] R1479, A NOVEL NUCLEOSIDE ANALOG AND POTENT INHIBITOR OF HCV REPLICATION, DOES NOT AFFECT RIBAVIRIN-INDUCED HEMOLYSIS AND ERYTHROCYTE FRAGILITY IN VITRO

The same mutation that encodes low-level human immunodeficiency virus type 1 resistance to 2',3'-dideoxyinosine and 2',3'-dideoxycytidine confers high-level resistance to the (-) enantiomer of 2',3'-dideoxy-3'-thiacytidine

Resistance to enfuvirtide, the first HIV fusion inhibitor

[790] IN VITRO RESISTANCE SELECTION TO THE HCV NUCLEOSIDE POLYMERASE INHIBITOR R1479 AND TO THE PROTEASE INHIBITOR VX-950

In vitro resistance development for RO-0335, a novel diphenylether nonnucleoside reverse transcriptase inhibitor

The separated enantiomers of 2'-deoxy-3'-thiacytidine (BCH 189) both inhibit human immunodeficiency virus replication in vitro

951 SILIBININ INHIBITS HCV REPLICATION IN VITRO

21 LOW LEVEL OF RESISTANCE, LOW VIRAL FITNESS AND ABSENCE OF RESISTANCE MUTATIONS IN BASELINE QUASISPECIES MAY CONTRIBUTE TO HIGH BARRIER TO R1626 RESISTANCE IN VIVO

952 2′ -DEOXY-NUCLEOSIDE ANALOGS AS POTENT DUAL INHIBITORS OF HCV AND HIV REPLICATION, WITH SELECTIVITY AGAINST OTHER VIRAL AND HUMAN POLYMERASES

Existence of hepatitis C virus NS5B variants naturally resistant to non-nucleoside, but not to nucleoside, polymerase inhibitors among untreated patients

851 ANTIVIRAL POTENCY OF R1479, ACTIVE COMPOUND DERIVED IN VIVO FROM PRODRUG R1626, DEMONSTRATED ACROSS HCV GENOTYPES 1-6 IN NS5B RECOMBINANT ENZYMES AND HCV REPLICONS

[622] R1479, A NOVEL HEPATITIS C POLYMERASE INHIBITOR: LACK OF PRE-EXISTING RESISTANCE MUTATION SUPPORTS THE OBSERVED IN VIVO HIGH BARRIER TO RESISTANCE

(-)-2'-deoxy-3'-thiacytidine is a potent, highly selective inhibitor of human immunodeficiency virus type 1 and type 2 replication in vitro

Ions required for the electrogenic transport of GABA by horizontal cells of the catfish retina

Evaluation of Reproductive Development Following Intravenous and Oral Exposure to DEHP in Male Neonatal Rats

Suchergebnisse filtern